Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 3
2005 4
2006 7
2007 5
2008 9
2009 10
2010 10
2011 13
2012 10
2013 14
2014 13
2015 12
2016 10
2017 11
2018 10
2019 10
2020 9
2021 13
2022 13
2023 17
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Results by year

Filters applied: . Clear all
Page 1
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
Tentori CA, Zhao LP, Tinterri B, Strange KE, Zoldan K, Dimopoulos K, Feng X, Riva E, Lim B, Simoni Y, Murthy V, Hayes MJ, Poloni A, Padron E, Cardoso BA, Cross M, Winter S, Santaolalla A, Patel BA, Groarke EM, Wiseman DH, Jones K, Jamieson L, Manogaran C, Daver N, Gallur L, Ingram W, Ferrell PB, Sockel K, Dulphy N, Chapuis N, Kubasch AS, Olsnes AM, Kulasekararaj A, De Lavellade H, Kern W, Van Hemelrijck M, Bonnet D, Westers TM, Freeman S, Oelschlaegel U, Valcarcel D, Raddi MG, Grønbæk K, Fontenay M, Loghavi S, Santini V, Almeida AM, Irish JM, Sallman DA, Young NS, van de Loosdrecht AA, Adès L, Della Porta MG, Cargo C, Platzbecker U, Kordasti S; i4MDS consortium. Tentori CA, et al. Among authors: van de loosdrecht aa. Hemasphere. 2024 May 15;8(5):e64. doi: 10.1002/hem3.64. eCollection 2024 May. Hemasphere. 2024. PMID: 38756352 Free PMC article.
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Sirenko M, Bernard E, Creignou M, Domenico D, Farina A, Arango Ossa JE, Kosmider O, Hasserjian RP, Jädersten M, Germing U, Sanz GF, van de Loosdrecht AA, Gurnari C, Follo MY, Thol FR, Zamora L, Pinheiro RF, Pellagatti A, Elias HK, Haase DT, Sander B, Orna E, Zoldan K, Eder LN, Sperr WR, Thalhammer R, Ganster C, Adès L, Tobiasson M, Palomo L, Della Porta MG, Huberman KH, Fenaux P, Belickova M, Savona MR, Klimek V, Santos FPS, Boultwood J, Kotsianidis I, Santini V, Sole F, Platzbecker U, Heuser M, Valent P, Finelli C, Voso MT, Shih LY, Ogawa S, Fontenay M, Jansen JH, Cervera J, Ebert BL, Bejar R, Greenberg PL, Gattermann N, Malcovati L, Cazzola M, Beck DB, Hellstrom-Lindberg ES, Papaemmanuil E. Sirenko M, et al. Among authors: van de loosdrecht aa. Blood. 2024 Apr 30:blood.2023023723. doi: 10.1182/blood.2023023723. Online ahead of print. Blood. 2024. PMID: 38687605
Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling.
Hermans SJF, van Norden Y, Versluis J, Rijneveld AW, van der Holt B, de Weerdt O, Biemond BJ, van de Loosdrecht AA, van der Wagen LE, Bellido M, van Gelder M, van der Velden WJFM, Selleslag D, van Lammeren-Venema D, van der Velden VHJ, de Wreede LC, Postmus D, Pignatti F, Cornelissen JJ. Hermans SJF, et al. Among authors: van de loosdrecht aa. Cancer Med. 2024 May;13(9):e6756. doi: 10.1002/cam4.6756. Cancer Med. 2024. PMID: 38680089 Free PMC article. Clinical Trial.
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.
Tettero JM, Heidinga ME, Mocking TR, Fransen G, Kelder A, Scholten WJ, Snel AN, Ngai LL, Bachas C, van de Loosdrecht AA, Ossenkoppele GJ, de Leeuw DC, Cloos J, Janssen JJWM. Tettero JM, et al. Among authors: van de loosdrecht aa. Leukemia. 2024 Mar;38(3):630-639. doi: 10.1038/s41375-024-02158-1. Epub 2024 Jan 25. Leukemia. 2024. PMID: 38272991 Free PMC article.
Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML.
Tettero JM, Buisman Y, Ngai LL, Bachas C, Gjertsen BT, Kelder A, van de Loosdrecht AA, Manz MG, Pabst T, Scholten W, Ossenkoppele GJ, Cloos J, de Leeuw DC. Tettero JM, et al. Among authors: van de loosdrecht aa. Hemasphere. 2023 Nov 21;7(12):e981. doi: 10.1097/HS9.0000000000000981. eCollection 2023 Dec. Hemasphere. 2023. PMID: 38026789 Free PMC article. No abstract available.
Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001.
Janssen LLG, Westers TM, Rovers J, Valk PJM, Cloos J, de Gruijl TD, van de Loosdrecht AA. Janssen LLG, et al. Among authors: van de loosdrecht aa. Hemasphere. 2023 Nov 2;7(11):e968. doi: 10.1097/HS9.0000000000000968. eCollection 2023 Nov. Hemasphere. 2023. PMID: 37928626 Free PMC article. No abstract available.
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Hilberink JR, van Zeventer IA, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, Valk PJM, Cloos J, van de Loosdrecht AA, Breems D, van Lammeren-Venema D, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz MG, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel MWM, Legdeur MC, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research (SAKK); Huls G. Hilberink JR, et al. Among authors: van de loosdrecht aa. Blood Cancer J. 2023 Jun 19;13(1):93. doi: 10.1038/s41408-023-00850-6. Blood Cancer J. 2023. PMID: 37336890 Free PMC article.
170 results